TITLE

SHIRES' OPTION FOR RIGHTS TO EMITASOL EXPIRES

PUB. DATE
December 2001
SOURCE
Worldwide Biotech;Dec2001, Vol. 13 Issue 12, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports the expiration of Shire Pharmaceuticals Group's option to acquire the exclusive rights to market the intranasal metaclopramide Emitasol from Questcor Pharmaceuticals Inc. in North America. Information on emitasol and emesis; Views of the American Cancer Society on the drug; Details on the drug's distribution in Europe.
ACCESSION #
7121010

 

Related Articles

  • Assets for Advantage. Looney, William // Pharmaceutical Executive;Feb2010, Vol. 30 Issue 2, p10 

    An introduction to the journal is presented in which the editor discusses an article on the survey from Hay Group on Sales Force Effectiveness, the profile of Shire Pharmaceuticals Group PLC, and the fourth annual choice of the Drug Brand of the Year.

  • INTUNIV.  // Physician Assistants' Prescribing Reference;Winter2009, Vol. 16 Issue 4, pA19 

    The article evaluates the medicine Intuniv from Shire Pharmaceuticals Group PLC.

  • Pharmaceuticals In Brief.  // Chemical Market Reporter;8/13/2001, Vol. 260 Issue 7, p8 

    Reports on the approval received by Shire Pharmaceuticals Group for Adderall XR drug.

  • NEWSLINE.  // MPR - Pharmacist's Edition;Spring2011, Vol. 5 Issue 1, pA.12 

    The article presents several drugs and vitamins for various diseases including Intuniv from Shire Pharmaceuticals Group PLC, the prenatal vitamin Nexa Select, and Zolpimist from NovaDel Pharma and ECR Pharmaceuticals.

  • Shire to submit new drug application to FDA for dry eye disease.  // Optometry Times;Jun2014, Vol. 6 Issue 6, p6 

    The article reports on the plan by pharmaceutical company Shire to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lifitegrast for the treatment of dry eye disease in adults in first-quarter 2015.

  • Suprecur.  // Royal Society of Medicine: Medicines;2002, p518 

    The article presents information on the drug suprecur developed by Shire Pharmaceuticals Inc. Suprecur is a proprietary, prescription-only preparation of the hormone buserelin. It can be used in women to treat endometriosis and in infertility treatment. It is available as a nasal spray and in a...

  • Reminyl.  // Nurse Prescribing;Jun2006, Vol. 4 Issue 5, p214 

    The article reports on the availability of Reminyl 8 mg and 12 mg tablets following the discontinuation of the distribution of the drugs in Great Britain and Ireland. Shire Pharmaceuticals will continue to provide the drugs into the market. The drug will also be made available as a 4 mg/ml oral...

  • INTUNIV.  // Monthly Prescribing Reference;Nov2009, Vol. 25 Issue 11, pA17 

    The article evaluates the drug Intuniv from Shire Pharmaceuticals Group PLC.

  • Shire Buys Orphan-Drug Firm. Investor's Business Daily // Investors Business Daily;11/3/2015, pA01 

    9 The Irish drugmaker agreed to pay $5.9 bil cash, or $37.30 a share, for

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics